U.S. markets closed

WISeKey International Holding AG (WKEY)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.95-0.35 (-4.79%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close7.30
Open7.14
Bid6.95 x 1400
Ask7.05 x 1300
Day's Range6.91 - 7.27
52 Week Range5.00 - 22.40
Volume406,016
Avg. Volume884,287
Market Cap145.884M
Beta (5Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)-3.35
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • WISeKey International Holding A
    Analyst Report: Seagen Inc.Seagen Inc. (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer and Tukysa for breast cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more